Latest Manufacturing And Distribution News

Page 1 of 10
Orica delivered its highest earnings in more than 15 years, lifting FY2026 EBIT 7% to A$1.06 billion and increasing its unfranked dividend 12% to 64 cents a share. Strong growth from Digital Solutions and Specialty Mining Chemicals helped offset currency pressure, litigation costs and a softer Indonesian coal market.
Victor Sage
Victor Sage
12 Nov 2026
Radiopharm Theranostics has reached final alignment with the U.S. FDA on a single pivotal Phase 3 trial for RAD101, its brain metastases imaging agent. The approximately 280-patient study is expected to begin dosing in the first half of 2027, moving the program from regulatory planning towards execution.
Ada Torres
Ada Torres
4 Nov 2026
Lennox is replacing the head of its Building Climate Solutions segment with an internal executive while retaining the outgoing leader as a strategic adviser through February 2028. The transition preserves customer and leadership continuity, but the filing does not indicate any change to financial guidance.
Maxwell Dee
Maxwell Dee
3 Nov 2026
Nexsen has secured ISO 13485 certification covering the design, development and manufacture of its StrepSure Group B Streptococcus diagnostic. The milestone strengthens the product’s regulatory and manufacturing platform, but does not yet amount to FDA or TGA approval.
Ada Torres
Ada Torres
2 Nov 2026
Radiopharm Theranostics is preparing to start a pivotal RAD101 brain-metastases imaging trial in early 2027 after a successful FDA meeting. The clinical progress comes with a sharper funding question: the company reported A$7.46 million in cash against A$10.69 million of quarterly operating outflows, before a subsequent A$8 million tax-incentive-backed advance.
Ada Torres
Ada Torres
30 Oct 2026
Argent BioPharma has granted Thai Phytomed International exclusive global commercialisation rights to four cannabis genotypes under a 10-year agreement. The deal preserves Argent’s ownership, but royalties depend on TPI generating profitable sales and securing approvals across multiple markets.
Victor Sage
Victor Sage
27 Oct 2026
Sparc Technologies has signed a non-exclusive MoU with UK graphene producer Levidian Nanosystems to develop and commercialise ecosparc-enhanced coatings across the GCC. The agreement sets targets for a binding commercial deal within 12 months and potential UAE manufacturing within 24 months, but commits neither sales nor revenue.
Victor Sage
Victor Sage
16 Oct 2026
ECS Botanics is taking six Australian-grown medicinal cannabis flower products into the UK through Curaleaf Laboratories, with initial supply targeted for November. The two-year deal offers access to UK sell-through but no guaranteed volumes, revenue or minimum purchases.
Victor Sage
Victor Sage
7 Oct 2026
Radiopharm says the FDA has provided a clear framework for the pivotal development of RAD101, its investigational brain metastases imaging agent. The company is preparing for Phase 3 while awaiting formal meeting minutes that could still refine the trial design and regulatory requirements.
Victor Sage
Victor Sage
5 Oct 2026
Radiopharm Theranostics reported a A$56.3 million comprehensive loss for fiscal 2026, with operating cash outflows rising to A$52.8 million and cash falling to A$4.1 million. The company says further funding is required, while auditors flag a material uncertainty over its ability to continue as a going concern.
Victor Sage
Victor Sage
30 Sept 2026
Immuron delivered record FY26 sales, a narrower loss and a much stronger cash balance, while shifting clinical development towards commercial partners. The annual report also flags a material weakness in inventory controls and confirms that IMM-529 remains dependent on a future licensing deal.
Victor Sage
Victor Sage
24 Sept 2026
Telix will acquire ITM in a proposed US$1.65 billion deal that combines a commercial radioisotope supplier with Telix’s precision medicine and therapeutic pipeline. The transaction could give Telix greater supply-chain control and entry into a validated cancer treatment market, but it also brings dilution, integration risk and an unresolved FDA pathway for ITM-11.
Ada Torres
Ada Torres
21 Sept 2026

Browse the archive

Full archive